Marilena Serra

Lecce, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patients.

Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patients.

Journal: British journal of haematology

Published: January 23, 2026

Liver Diffusion Weighted MRI: Effect of Iron Overload on Apparent Diffusion Coefficient.

Liver Diffusion Weighted MRI: Effect of Iron Overload on Apparent Diffusion Coefficient.

Journal: NMR in biomedicine

Published: January 08, 2026

Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With β-Thalassemia.

Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With β-Thalassemia.

Journal: American journal of hematology

Published: August 15, 2025

Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.

Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.

Journal: Blood advances

Published: June 26, 2025

Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.

Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.

Journal: Blood advances

Published: June 26, 2025

Lifetime Risk of Liver Disease in Patients With β-Thalassemia: Data From the de-LIGHT Retrospective Cohort Study.

Lifetime Risk of Liver Disease in Patients With β-Thalassemia: Data From the de-LIGHT Retrospective Cohort Study.

Journal: European journal of haematology

Published: April 26, 2025

Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study.

Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study.

Journal: British journal of haematology

Published: March 13, 2025

Pancreatic Volume in Thalassemia: Determinants and Association with Alterations of Glucose Metabolism.

Pancreatic Volume in Thalassemia: Determinants and Association with Alterations of Glucose Metabolism.

Journal: Diagnostics (Basel, Switzerland)

Published: December 16, 2024

Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national database.

Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national database.

Journal: British journal of haematology

Published: November 22, 2024

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy.

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy.

Journal: Blood advances

Published: August 24, 2022

Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.

Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.

Journal: American journal of hematology

Published: October 29, 2021

Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.

Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.

Journal: Haematologica

Published: September 18, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026